Q3 Earnings Estimate for BBIO Issued By Leerink Partnrs

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Equities research analysts at Leerink Partnrs issued their Q3 2025 earnings estimates for BridgeBio Pharma in a research report issued on Monday, February 24th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings of ($0.94) per share for the quarter. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma’s Q4 2025 earnings at ($0.89) EPS.

Other analysts have also issued reports about the stock. Scotiabank upped their price target on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the stock a “sector outperform” rating in a research note on Friday, February 21st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $95.00 target price on shares of BridgeBio Pharma in a research report on Friday, February 21st. Citigroup increased their price target on BridgeBio Pharma from $45.00 to $49.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Evercore ISI boosted their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a report on Monday, December 23rd. Finally, Bank of America raised their target price on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, November 25th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.67.

BridgeBio Pharma Stock Down 5.2 %

Shares of NASDAQ:BBIO opened at $34.35 on Tuesday. The company’s 50-day moving average price is $32.20 and its 200 day moving average price is $28.13. The company has a market cap of $6.53 billion, a PE ratio of -12.05 and a beta of 1.07. BridgeBio Pharma has a fifty-two week low of $21.62 and a fifty-two week high of $39.47.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The company had revenue of $5.88 million during the quarter, compared to analyst estimates of $4.04 million.

Insider Activity

In other BridgeBio Pharma news, CFO Brian C. Stephenson sold 68,000 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total transaction of $2,467,720.00. Following the transaction, the chief financial officer now owns 93,758 shares in the company, valued at approximately $3,402,477.82. This trade represents a 42.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Neil Kumar sold 326,932 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total transaction of $11,864,362.28. Following the transaction, the chief executive officer now owns 5,371,515 shares of the company’s stock, valued at approximately $194,932,279.35. This represents a 5.74 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,496,239 shares of company stock valued at $122,612,036 over the last three months. 24.66% of the stock is owned by insiders.

Institutional Trading of BridgeBio Pharma

Large investors have recently bought and sold shares of the business. Mackenzie Financial Corp raised its holdings in shares of BridgeBio Pharma by 6.6% during the fourth quarter. Mackenzie Financial Corp now owns 9,505 shares of the company’s stock worth $261,000 after acquiring an additional 592 shares during the period. GF Fund Management CO. LTD. bought a new position in BridgeBio Pharma during the 4th quarter worth about $109,000. Frazier Life Sciences Management L.P. raised its stake in shares of BridgeBio Pharma by 1.1% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company’s stock valued at $104,285,000 after purchasing an additional 40,000 shares during the period. Woodline Partners LP lifted its holdings in shares of BridgeBio Pharma by 132.9% in the fourth quarter. Woodline Partners LP now owns 2,211,521 shares of the company’s stock valued at $60,684,000 after purchasing an additional 1,261,772 shares in the last quarter. Finally, Zimmer Partners LP acquired a new position in shares of BridgeBio Pharma during the fourth quarter worth about $4,950,000. 99.85% of the stock is owned by institutional investors.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.